{"name":"Bausch & Lomb Incorporated","slug":"bausch-lomb-incorporated","ticker":"","exchange":"","domain":"bauschlombincorporated.com","description":"","hq":"Rochester","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-09-01","label":"Plasmin Phase 3 readout (Melanoma)","drug":"Plasmin","drugSlug":"plasmin","type":"phase3_readout","sentiment":"neutral"},{"date":"2028-10-01","label":"Plasmin Phase 3 readout (Hemorrhagic Shock, Trauma Injury)","drug":"Plasmin","drugSlug":"plasmin","type":"phase3_readout","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":24,"colorKey":"neuroscience","drugs":[{"name":"Bepotastine besilate-fluticasone propionate","genericName":"Bepotastine besilate-fluticasone propionate","slug":"bepotastine-besilate-fluticasone-propionate","indication":"Allergic conjunctivitis","status":"phase_2"},{"name":"Dexamethasone 0.1% and tobramycin 0.3%","genericName":"Dexamethasone 0.1% and tobramycin 0.3%","slug":"dexamethasone-0-1-and-tobramycin-0-3","indication":"Other","status":"marketed"},{"name":"Ecabet 3.70%","genericName":"Ecabet 3.70%","slug":"ecabet-3-70","indication":"Gastroprotection in patients with gastric ulcers","status":"phase_2"},{"name":"ISV-403","genericName":"ISV-403","slug":"isv-403","indication":"Corneal neovascularization","status":"phase_3"},{"name":"Perfluorohexyloctane ophthalmic solution","genericName":"Perfluorohexyloctane ophthalmic solution","slug":"perfluorohexyloctane-ophthalmic-solution","indication":"Other","status":"marketed"},{"name":"Plasmin","genericName":"Plasmin","slug":"plasmin","indication":"Other","status":"discontinued"},{"name":"Vitrase","genericName":"Vitrase","slug":"vitrase","indication":"Other","status":"marketed"},{"name":"fluocinolone acetonide intravitreal implant","genericName":"fluocinolone acetonide intravitreal implant","slug":"fluocinolone-acetonide-intravitreal-implant","indication":"Other","status":"marketed"},{"name":"instillation of NOV03","genericName":"instillation of NOV03","slug":"instillation-of-nov03","indication":"Other","status":"marketed"},{"name":"BL1107 Low dose","genericName":"BL1107 Low dose","slug":"bl1107-low-dose","indication":"Other","status":"phase_2"},{"name":"Bepotastine Besilate Nasal Spray 3% Twice a day","genericName":"Bepotastine Besilate Nasal Spray 3% Twice a day","slug":"bepotastine-besilate-nasal-spray-3-twice-a-day","indication":"Other","status":"phase_2"},{"name":"Bepotastine besilate formulation","genericName":"Bepotastine besilate formulation","slug":"bepotastine-besilate-formulation","indication":"Allergic conjunctivitis","status":"phase_3"},{"name":"Brimonidine tartrate ophthalmic solution 0.025%","genericName":"Brimonidine tartrate ophthalmic solution 0.025%","slug":"brimonidine-tartrate-ophthalmic-solution-0-025","indication":"Other","status":"marketed"},{"name":"EM-100","genericName":"EM-100","slug":"em-100","indication":"Corneal neovascularization","status":"phase_3"},{"name":"Ecabet 2.83%","genericName":"Ecabet 2.83%","slug":"ecabet-2-83","indication":"Other","status":"phase_2"},{"name":"Indomethacin ophthalmic solution","genericName":"Indomethacin ophthalmic solution","slug":"indomethacin-ophthalmic-solution","indication":"Other","status":"marketed"},{"name":"Ketotifen/naphazoline","genericName":"Ketotifen/naphazoline","slug":"ketotifen-naphazoline","indication":"Allergic conjunctivitis","status":"phase_3"},{"name":"Loteprednol and tobramycin","genericName":"Loteprednol and tobramycin","slug":"loteprednol-and-tobramycin","indication":"Other","status":"marketed"},{"name":"Loteprednol etabonate 0.5% and tobramycin 0.3%","genericName":"Loteprednol etabonate 0.5% and tobramycin 0.3%","slug":"loteprednol-etabonate-0-5-and-tobramycin-0-3","indication":"Other","status":"marketed"},{"name":"Olopatadine 0.1%","genericName":"Olopatadine 0.1%","slug":"olopatadine-0-1","indication":"Allergic conjunctivitis","status":"marketed"},{"name":"Prednisolones acetate","genericName":"Prednisolones acetate","slug":"prednisolones-acetate","indication":"Treatment of uveitis","status":"phase_3"},{"name":"Vehicle (TID)","genericName":"Vehicle (TID)","slug":"vehicle-tid","indication":"Other","status":"phase_3"},{"name":"WB007 0.05%","genericName":"WB007 0.05%","slug":"wb007-0-05","indication":"Other","status":"phase_1"},{"name":"bepotastine besilate ophthalmic solution","genericName":"bepotastine besilate ophthalmic solution","slug":"bepotastine-besilate-ophthalmic-solution","indication":"Allergic conjunctivitis","status":"marketed"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":12,"colorKey":"cardiovascular","drugs":[{"name":"BOL-303259-X","genericName":"BOL-303259-X","slug":"bol-303259-x","indication":"Geographic atrophy (age-related macular degeneration)","status":"phase_3"},{"name":"BTOS-HA","genericName":"BTOS-HA","slug":"btos-ha","indication":"Dry eye disease / Keratoconjunctivitis sicca","status":"phase_3"},{"name":"Experimental: Vehicle ophthalmic solution","genericName":"Experimental: Vehicle ophthalmic solution","slug":"experimental-vehicle-ophthalmic-solution","indication":"Ophthalmic indication (specific indication not disclosed for this vehicle formulation)","status":"phase_3"},{"name":"Ketotifen Fumarate 0.035%","genericName":"Ketotifen Fumarate 0.035%","slug":"ketotifen-fumarate-0-035","indication":"Allergic conjunctivitis","status":"phase_3"},{"name":"Loteprednol etabonate 0.2%","genericName":"Loteprednol etabonate 0.2%","slug":"loteprednol-etabonate-0-2","indication":"Inflammation and pain following ocular surgery","status":"marketed"},{"name":"Lumify®","genericName":"Lumify®","slug":"lumify","indication":"Reduction of conjunctival redness due to minor eye irritation","status":"marketed"},{"name":"Miebo","genericName":"Miebo","slug":"miebo","indication":"Dry eye disease","status":"marketed"},{"name":"Soothe® Lubricant Eye Drops","genericName":"Soothe® Lubricant Eye Drops","slug":"soothe-lubricant-eye-drops","indication":"Dry eye syndrome / dry eye disease","status":"marketed"},{"name":"T-Pred","genericName":"T-Pred","slug":"t-pred","indication":"Treatment of inflammation and pain in the eye","status":"phase_3"},{"name":"Vehicle Gel (BID)","genericName":"Vehicle Gel (BID)","slug":"vehicle-gel-bid","indication":"Dry eye syndrome","status":"phase_3"},{"name":"Zaditor®","genericName":"Zaditor®","slug":"zaditor","indication":"Allergic conjunctivitis (itching of the eye due to allergies)","status":"marketed"},{"name":"pegaptanib sodium injection","genericName":"pegaptanib sodium injection","slug":"pegaptanib-sodium-injection","indication":"Neovascular (wet) age-related macular degeneration","status":"marketed"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":8,"colorKey":"immunology","drugs":[{"name":"BL1107 High dose","genericName":"BL1107 High dose","slug":"bl1107-high-dose","indication":"Treatment of acute postoperative inflammation and pain following cataract surgery","status":"phase_2"},{"name":"KetoNaph","genericName":"KetoNaph","slug":"ketonaph","indication":"Postoperative inflammation and pain following cataract surgery","status":"phase_3"},{"name":"bromfenac ophthalmic solution","genericName":"bromfenac ophthalmic solution","slug":"bromfenac-ophthalmic-solution","indication":"Postoperative inflammation and ocular pain after cataract surgery","status":"marketed"},{"name":"vehicle of loteprednol etabonate","genericName":"vehicle of loteprednol etabonate","slug":"vehicle-of-loteprednol-etabonate","indication":"Treatment of postoperative inflammation and pain following ocular surgery","status":"phase_3"},{"name":"Bromfenac Ophthalmic Solution A","genericName":"Bromfenac Ophthalmic Solution A","slug":"bromfenac-ophthalmic-solution-a","indication":"Postoperative inflammation and pain following ocular surgery","status":"phase_3"},{"name":"Bromfenac Ophthalmic Solution B","genericName":"Bromfenac Ophthalmic Solution B","slug":"bromfenac-ophthalmic-solution-b","indication":"Postoperative inflammation and pain following cataract surgery","status":"marketed"},{"name":"Ketorolac Ophthalmic Solution","genericName":"Ketorolac Ophthalmic Solution","slug":"ketorolac-ophthalmic-solution","indication":"Postoperative ocular pain and inflammation following cataract surgery","status":"marketed"},{"name":"Vehicle of Ophthalmic Loteprednol Etabonate","genericName":"Vehicle of Ophthalmic Loteprednol Etabonate","slug":"vehicle-of-ophthalmic-loteprednol-etabonate","indication":"Treatment of inflammation and pain associated with ocular surgery","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":8,"colorKey":"infectious","drugs":[{"name":"Tobramycin and dexamethasone ophthalmic suspension","genericName":"Tobramycin and dexamethasone ophthalmic suspension","slug":"tobramycin-and-dexamethasone-ophthalmic-suspension","indication":"Bacterial conjunctivitis","status":"marketed"},{"name":"BOL-303242-X","genericName":"BOL-303242-X","slug":"bol-303242-x","indication":"Non-infectious uveitis","status":"phase_2"},{"name":"NOV03","genericName":"NOV03","slug":"nov03","indication":"Treatment of COVID-19","status":"phase_3"},{"name":"Prednisolone and Tobramycin","genericName":"Prednisolone and Tobramycin","slug":"prednisolone-and-tobramycin","indication":"Ocular inflammation with bacterial infection risk","status":"phase_3"},{"name":"Tobramycin and dexamethasone","genericName":"Tobramycin and dexamethasone","slug":"tobramycin-and-dexamethasone","indication":"Bacterial conjunctivitis","status":"marketed"},{"name":"Vehicle of Zylet","genericName":"Vehicle of Zylet","slug":"vehicle-of-zylet","indication":"Steroid-responsive inflammatory ocular conditions where bacterial infection or risk of bacterial infection exists","status":"marketed"},{"name":"loteprednol etabonate and tobramycin","genericName":"loteprednol etabonate and tobramycin","slug":"loteprednol-etabonate-and-tobramycin","indication":"Steroid-responsive inflammatory ocular conditions","status":"marketed"},{"name":"loteprednol etabonate/tobramycin opthalmic suspension","genericName":"loteprednol etabonate/tobramycin opthalmic suspension","slug":"loteprednol-etabonate-tobramycin-opthalmic-suspension","indication":"Steroid-responsive inflammatory ocular conditions with bacterial infection or risk of bacterial infection","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Azopt 1%","genericName":"Azopt 1%","slug":"azopt-1","indication":"Glaucoma","status":"phase_3"},{"name":"brinzolamide 1% ophthalmic suspension","genericName":"brinzolamide 1% ophthalmic suspension","slug":"brinzolamide-1-ophthalmic-suspension","indication":"Treatment of elevated intraocular pressure in patients with ocular hypertension or glaucoma","status":"phase_3"}]}],"pipeline":[{"name":"Azopt 1%","genericName":"Azopt 1%","slug":"azopt-1","phase":"phase_3","mechanism":"Azopt is a topical carbonic anhydrase inhibitor that reduces intraocular pressure by decreasing aqueous humor production in the eye.","indications":["Glaucoma","Ocular hypertension"],"catalyst":""},{"name":"BL1107 High dose","genericName":"BL1107 High dose","slug":"bl1107-high-dose","phase":"phase_2","mechanism":"BL1107 High dose is an anti-inflammatory agent.","indications":["Treatment of acute postoperative inflammation and pain following cataract surgery"],"catalyst":""},{"name":"BOL-303259-X","genericName":"BOL-303259-X","slug":"bol-303259-x","phase":"phase_3","mechanism":"BOL-303259-X is a small molecule that inhibits the complement C5 pathway to reduce inflammation and tissue damage in the eye.","indications":["Geographic atrophy (age-related macular degeneration)"],"catalyst":""},{"name":"BTOS-HA","genericName":"BTOS-HA","slug":"btos-ha","phase":"phase_3","mechanism":"BTOS-HA is a hyaluronic acid-based ophthalmic formulation designed to provide sustained lubrication and protection to the ocular surface.","indications":["Dry eye disease / Keratoconjunctivitis sicca"],"catalyst":""},{"name":"Bepotastine besilate-fluticasone propionate","genericName":"Bepotastine besilate-fluticasone propionate","slug":"bepotastine-besilate-fluticasone-propionate","phase":"phase_2","mechanism":"Histamine H1 receptor antagonist and corticosteroid combination","indications":["Allergic conjunctivitis"],"catalyst":""},{"name":"Dexamethasone 0.1% and tobramycin 0.3%","genericName":"Dexamethasone 0.1% and tobramycin 0.3%","slug":"dexamethasone-0-1-and-tobramycin-0-3","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ecabet 3.70%","genericName":"Ecabet 3.70%","slug":"ecabet-3-70","phase":"phase_2","mechanism":"Ecabet is a gastroprotective agent that acts as a mucosal protective agent.","indications":["Gastroprotection in patients with gastric ulcers"],"catalyst":""},{"name":"ISV-403","genericName":"ISV-403","slug":"isv-403","phase":"phase_3","mechanism":"ISV-403 is a small molecule that inhibits the Wnt/β-catenin signaling pathway to reduce corneal neovascularization and inflammation.","indications":["Corneal neovascularization","Corneal scarring and fibrosis"],"catalyst":""},{"name":"KetoNaph","genericName":"KetoNaph","slug":"ketonaph","phase":"phase_3","mechanism":"KetoNaph is a topical nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes to reduce inflammation and pain in the eye.","indications":["Postoperative inflammation and pain following cataract surgery","Postoperative inflammation and pain following refractive surgery"],"catalyst":""},{"name":"Perfluorohexyloctane ophthalmic solution","genericName":"Perfluorohexyloctane ophthalmic solution","slug":"perfluorohexyloctane-ophthalmic-solution","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Plasmin","genericName":"Plasmin","slug":"plasmin","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Tobramycin and dexamethasone ophthalmic suspension","genericName":"Tobramycin and dexamethasone ophthalmic suspension","slug":"tobramycin-and-dexamethasone-ophthalmic-suspension","phase":"marketed","mechanism":"Tobramycin kills bacteria by inhibiting protein synthesis, while dexamethasone reduces inflammation and immune response in the eye.","indications":["Bacterial conjunctivitis","Bacterial keratitis","Ocular inflammation associated with bacterial infection"],"catalyst":""},{"name":"Vitrase","genericName":"Vitrase","slug":"vitrase","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"bromfenac ophthalmic solution","genericName":"bromfenac ophthalmic solution","slug":"bromfenac-ophthalmic-solution","phase":"marketed","mechanism":"Small molecule","indications":["Postoperative inflammation and ocular pain after cataract surgery"],"catalyst":""},{"name":"fluocinolone acetonide intravitreal implant","genericName":"fluocinolone acetonide intravitreal implant","slug":"fluocinolone-acetonide-intravitreal-implant","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"instillation of NOV03","genericName":"instillation of NOV03","slug":"instillation-of-nov03","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"vehicle of loteprednol etabonate","genericName":"vehicle of loteprednol etabonate","slug":"vehicle-of-loteprednol-etabonate","phase":"phase_3","mechanism":"Loteprednol etabonate is a corticosteroid that works by inhibiting the inflammatory response.","indications":["Treatment of postoperative inflammation and pain following ocular surgery"],"catalyst":""},{"name":"BL1107 Low dose","genericName":"BL1107 Low dose","slug":"bl1107-low-dose","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BOL-303242-X","genericName":"BOL-303242-X","slug":"bol-303242-x","phase":"phase_2","mechanism":"BOL-303242-X is a small molecule that targets the S1P1 receptor.","indications":["Non-infectious uveitis"],"catalyst":""},{"name":"Bepotastine Besilate Nasal Spray 3% Twice a day","genericName":"Bepotastine Besilate Nasal Spray 3% Twice a day","slug":"bepotastine-besilate-nasal-spray-3-twice-a-day","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Bepotastine besilate formulation","genericName":"Bepotastine besilate formulation","slug":"bepotastine-besilate-formulation","phase":"phase_3","mechanism":"Bepotastine besilate is a selective H1-receptor antagonist that blocks histamine signaling to reduce allergic symptoms.","indications":["Allergic conjunctivitis"],"catalyst":""},{"name":"Brimonidine tartrate ophthalmic solution 0.025%","genericName":"Brimonidine tartrate ophthalmic solution 0.025%","slug":"brimonidine-tartrate-ophthalmic-solution-0-025","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Bromfenac Ophthalmic Solution A","genericName":"Bromfenac Ophthalmic Solution A","slug":"bromfenac-ophthalmic-solution-a","phase":"phase_3","mechanism":"Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation in the eye.","indications":["Postoperative inflammation and pain following ocular surgery","Ocular itching associated with allergic conjunctivitis"],"catalyst":""},{"name":"Bromfenac Ophthalmic Solution B","genericName":"Bromfenac Ophthalmic Solution B","slug":"bromfenac-ophthalmic-solution-b","phase":"marketed","mechanism":"Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis in the eye.","indications":["Postoperative inflammation and pain following cataract surgery","Ocular itching associated with allergic conjunctivitis"],"catalyst":""},{"name":"EM-100","genericName":"EM-100","slug":"em-100","phase":"phase_3","mechanism":"EM-100 is a small molecule that inhibits the Wnt/β-catenin signaling pathway to reduce corneal neovascularization and inflammation.","indications":["Corneal neovascularization","Corneal scarring and opacity"],"catalyst":""},{"name":"Ecabet 2.83%","genericName":"Ecabet 2.83%","slug":"ecabet-2-83","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Experimental: Vehicle ophthalmic solution","genericName":"Experimental: Vehicle ophthalmic solution","slug":"experimental-vehicle-ophthalmic-solution","phase":"phase_3","mechanism":"A vehicle ophthalmic solution formulation designed to deliver therapeutic agents to the eye while maintaining ocular surface stability and drug bioavailability.","indications":["Ophthalmic indication (specific indication not disclosed for this vehicle formulation)"],"catalyst":""},{"name":"Indomethacin ophthalmic solution","genericName":"Indomethacin ophthalmic solution","slug":"indomethacin-ophthalmic-solution","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ketorolac Ophthalmic Solution","genericName":"Ketorolac Ophthalmic Solution","slug":"ketorolac-ophthalmic-solution","phase":"marketed","mechanism":"Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation in the eye.","indications":["Postoperative ocular pain and inflammation following cataract surgery","Allergic conjunctivitis","Ocular pain and photophobia associated with corneal abrasion or refractive surgery"],"catalyst":""},{"name":"Ketotifen Fumarate 0.035%","genericName":"Ketotifen Fumarate 0.035%","slug":"ketotifen-fumarate-0-035","phase":"phase_3","mechanism":"Ketotifen is a selective H1-receptor antagonist and mast cell stabilizer that prevents allergic reactions by blocking histamine release and reducing mast cell degranulation.","indications":["Allergic conjunctivitis","Itching associated with allergic conditions of the eye"],"catalyst":""},{"name":"Ketotifen/naphazoline","genericName":"Ketotifen/naphazoline","slug":"ketotifen-naphazoline","phase":"phase_3","mechanism":"Ketotifen is a mast cell stabilizer and H1-receptor antagonist, while naphazoline is a selective alpha-1 adrenergic agonist, together reducing allergic inflammation and vasoconstriction in the eye.","indications":["Allergic conjunctivitis","Ocular itching and redness associated with allergies"],"catalyst":""},{"name":"Loteprednol and tobramycin","genericName":"Loteprednol and tobramycin","slug":"loteprednol-and-tobramycin","phase":"marketed","mechanism":"Inflammatory mediators and bacterial protein synthesis","indications":[],"catalyst":""},{"name":"Loteprednol etabonate 0.2%","genericName":"Loteprednol etabonate 0.2%","slug":"loteprednol-etabonate-0-2","phase":"marketed","mechanism":"Loteprednol etabonate is a corticosteroid that suppresses inflammatory and immune responses in the eye by binding to glucocorticoid receptors.","indications":["Inflammation and pain following ocular surgery","Seasonal allergic conjunctivitis","Uveitis","Dry eye disease"],"catalyst":""},{"name":"Loteprednol etabonate 0.5% and tobramycin 0.3%","genericName":"Loteprednol etabonate 0.5% and tobramycin 0.3%","slug":"loteprednol-etabonate-0-5-and-tobramycin-0-3","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Lumify®","genericName":"Lumify®","slug":"lumify","phase":"marketed","mechanism":"Lumify is a selective alpha-1 adrenergic receptor agonist that constricts blood vessels in the eye to reduce redness.","indications":["Reduction of conjunctival redness due to minor eye irritation"],"catalyst":""},{"name":"Miebo","genericName":"Miebo","slug":"miebo","phase":"marketed","mechanism":"Small molecule","indications":["Dry eye disease"],"catalyst":""},{"name":"NOV03","genericName":"NOV03","slug":"nov03","phase":"phase_3","mechanism":"NOV03 is an investigational antiviral medication.","indications":["Treatment of COVID-19"],"catalyst":""},{"name":"Olopatadine 0.1%","genericName":"Olopatadine 0.1%","slug":"olopatadine-0-1","phase":"marketed","mechanism":"Olopatadine is a selective H1-receptor antagonist and mast cell stabilizer that reduces allergic inflammation in the eye.","indications":["Allergic conjunctivitis","Itching associated with allergic conjunctivitis"],"catalyst":""},{"name":"Prednisolone and Tobramycin","genericName":"Prednisolone and Tobramycin","slug":"prednisolone-and-tobramycin","phase":"phase_3","mechanism":"This combination uses prednisolone to suppress inflammation and tobramycin to provide topical antimicrobial coverage, typically for ocular infections or inflammatory conditions.","indications":["Ocular inflammation with bacterial infection risk","Post-operative ocular inflammation and infection prophylaxis"],"catalyst":""},{"name":"Prednisolones acetate","genericName":"Prednisolones acetate","slug":"prednisolones-acetate","phase":"phase_3","mechanism":"Prednisolone acetate is a corticosteroid that suppresses inflammation and immune responses by inhibiting the production of inflammatory cytokines and mediators.","indications":["Treatment of uveitis"],"catalyst":""},{"name":"Soothe® Lubricant Eye Drops","genericName":"Soothe® Lubricant Eye Drops","slug":"soothe-lubricant-eye-drops","phase":"marketed","mechanism":"Soothe® Lubricant Eye Drops provide ocular surface lubrication and protection by forming a protective film over the cornea and conjunctiva.","indications":["Dry eye syndrome / dry eye disease","Ocular irritation and discomfort"],"catalyst":""},{"name":"T-Pred","genericName":"T-Pred","slug":"t-pred","phase":"phase_3","mechanism":"T-Pred is a corticosteroid used to reduce inflammation and suppress the immune system.","indications":["Treatment of inflammation and pain in the eye"],"catalyst":""},{"name":"Tobramycin and dexamethasone","genericName":"Tobramycin and dexamethasone","slug":"tobramycin-and-dexamethasone","phase":"marketed","mechanism":"Tobramycin kills bacteria by inhibiting protein synthesis, while dexamethasone reduces inflammation and immune response in the eye.","indications":["Bacterial conjunctivitis","Bacterial keratitis","Ocular inflammation associated with bacterial infection"],"catalyst":""},{"name":"Vehicle (TID)","genericName":"Vehicle (TID)","slug":"vehicle-tid","phase":"phase_3","mechanism":"Vehicle (TID) is a treatment that does not have a known mechanism of action.","indications":[],"catalyst":""},{"name":"Vehicle Gel (BID)","genericName":"Vehicle Gel (BID)","slug":"vehicle-gel-bid","phase":"phase_3","mechanism":"Vehicle Gel is a topical ophthalmic gel used to lubricate and protect the eyes.","indications":["Dry eye syndrome","Blepharitis"],"catalyst":""},{"name":"Vehicle of Ophthalmic Loteprednol Etabonate","genericName":"Vehicle of Ophthalmic Loteprednol Etabonate","slug":"vehicle-of-ophthalmic-loteprednol-etabonate","phase":"phase_3","mechanism":"Loteprednol etabonate is a corticosteroid that reduces inflammation by inhibiting the production of prostaglandins.","indications":["Treatment of inflammation and pain associated with ocular surgery"],"catalyst":""},{"name":"Vehicle of Zylet","genericName":"Vehicle of Zylet","slug":"vehicle-of-zylet","phase":"marketed","mechanism":"The vehicle of Zylet is an inert pharmaceutical formulation base that serves as the delivery medium for the active pharmaceutical ingredients loteprednol etabonate and tobramycin.","indications":["Steroid-responsive inflammatory ocular conditions where bacterial infection or risk of bacterial infection exists"],"catalyst":""},{"name":"WB007 0.05%","genericName":"WB007 0.05%","slug":"wb007-0-05","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Zaditor®","genericName":"Zaditor®","slug":"zaditor","phase":"marketed","mechanism":"Zaditor is a selective H1-receptor antagonist and mast cell stabilizer that prevents allergic responses in the eye.","indications":["Allergic conjunctivitis (itching of the eye due to allergies)"],"catalyst":""},{"name":"bepotastine besilate ophthalmic solution","genericName":"bepotastine besilate ophthalmic solution","slug":"bepotastine-besilate-ophthalmic-solution","phase":"marketed","mechanism":"Bepotastine blocks H1 receptors and inhibits histamine release from mast cells.","indications":["Allergic conjunctivitis"],"catalyst":""},{"name":"brinzolamide 1% ophthalmic suspension","genericName":"brinzolamide 1% ophthalmic suspension","slug":"brinzolamide-1-ophthalmic-suspension","phase":"phase_3","mechanism":"Brinzolamide is a carbonic anhydrase inhibitor that reduces aqueous humor production in the eye.","indications":["Treatment of elevated intraocular pressure in patients with ocular hypertension or glaucoma","Secondary open-angle glaucoma"],"catalyst":""},{"name":"loteprednol etabonate and tobramycin","genericName":"loteprednol etabonate and tobramycin","slug":"loteprednol-etabonate-and-tobramycin","phase":"marketed","mechanism":"Small molecule","indications":["Steroid-responsive inflammatory ocular conditions","Inflammatory conditions of the palpebral and bulbar conjunctiva","Chronic anterior uveitis","Corneal injury from chemical, radiation, or thermal burns","Penetration of foreign bodies in the eye"],"catalyst":""},{"name":"loteprednol etabonate/tobramycin opthalmic suspension","genericName":"loteprednol etabonate/tobramycin opthalmic suspension","slug":"loteprednol-etabonate-tobramycin-opthalmic-suspension","phase":"marketed","mechanism":"Loteprednol etabonate reduces ocular inflammation via glucocorticoid receptor activation, while tobramycin provides broad-spectrum bacterial coverage by inhibiting bacterial protein synthesis.","indications":["Steroid-responsive inflammatory ocular conditions with bacterial infection or risk of bacterial infection","Post-operative ocular inflammation and infection prophylaxis"],"catalyst":""},{"name":"pegaptanib sodium injection","genericName":"pegaptanib sodium injection","slug":"pegaptanib-sodium-injection","phase":"marketed","mechanism":"Pegaptanib sodium is an aptamer that selectively binds and inhibits vascular endothelial growth factor (VEGF), reducing abnormal blood vessel growth in the eye.","indications":["Neovascular (wet) age-related macular degeneration"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPWk1HNWVPOURSa05mcWdfT1ljR2xlVjVxWDBMWGlTWFBONnh6dnVGaHJkSWg5cDdKMWxjMDJxdmZhV0EzOFpraFRLa2M5SnRhVWNheTQ4YjlNdWJiZ2h1N19Jc2lJRzlSMVVSZ1NLRUFTeDhkLTF0ZWhnTEFwNTM5UU9ZMWlfeFZYX3lzdTFfZjVfZG5Ec2Z6VGhPcHhEVnV2Q19WMWcwLWpHUQ?oc=5","date":"2026-02-11","type":"pipeline","source":"Fortune","summary":"Bausch + Lomb CEO: Standing still is the new falling behind - Fortune","headline":"Bausch + Lomb CEO: Standing still is the new falling behind","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQTnVZclRKazBBZ0tpT2hHYUJTZngzYVFQTTM1YTZsWnduX0xMQVFDaTh0RXlFS1QxcUhROW1ZM3pSNEJnbGp3eHkyYzluOXU4d0kxQVgxcHFyU3BOUklmMlpYZjh2eVlfWGRSUUlMbzVQa0hfZWs4VGpid1Z5SHo4REdqcHV6TGVBaXR2ZGs1anRZQnRT?oc=5","date":"2025-11-11","type":"pipeline","source":"Yahoo Finance","summary":"Viatris, Oscar Health, BioMarin Pharmaceutical, QuidelOrtho, and Bausch + Lomb Stocks Trade Up, What You Need To Know - Yahoo Finance","headline":"Viatris, Oscar Health, BioMarin Pharmaceutical, QuidelOrtho, and Bausch + Lomb Stocks Trade Up, What You Need To Know","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPbXNuV0hyNEc1SmdES2sxMGdndnpRNVktWl91YU9fYkFpUEZHeHRLWHVMbXBHSWlUSDRRU2NsRk5LUGxmWkZzLVZ1Ymp6SnN6SnpMdEYzUHZmbjFPRThQTmZTRGE5bjZ2Q3pHSlFYRkUtSFhnZFZlcjc2UU0xemUwZGlCYXNkSEhoVlJwRFVKd1hwaUFoZE5GSTA3QQ?oc=5","date":"2025-11-07","type":"pipeline","source":"Yahoo Finance","summary":"Will Pharmaceuticals Division Momentum and Updated Outlook Shift Bausch + Lomb's (BLCO) Investment Narrative? - Yahoo Finance","headline":"Will Pharmaceuticals Division Momentum and Updated Outlook Shift Bausch + Lomb's (BLCO) Investment Narrative?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxNd21rbXNqUmhqSmNfOGVOMUh4YkNNRjNKTmdmNm4yN2VZXzFyTV9IQzdqTWN1Ujhjalc4dFZ1Q2FaS3Q4a2k1Q3NtVVd1RnVYZWgxZExKR0pZWXZCSWRvcVZ5VEN5eG5NUDBfQm9iekg4YnNSdVdNdWRGRlc2MjljSG1WZlhEY3d4Ml9Cb21MTQ?oc=5","date":"2024-12-13","type":"pipeline","source":"The Pharma Letter","summary":"Bausch + Lomb responds to rumors of a potential sale - The Pharma Letter","headline":"Bausch + Lomb responds to rumors of a potential sale","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPOUFOWjBHOURnVnM0dXhMb3hBMG5FYW5Gakt2eVl2RVdkQklVZnNFNGFjM1A3a01tVnJNMkhJckdpSV81cXVkaXB3RjVRVFNtNFF6WG5PY1dyMjQ0b3BKdTd1VlNoRWtoWUxiWTdUV0RGZlA3Njg5TnVLTlI0eWVpdHIwZlppQjludURqSzlnc1A1QUh3M2J5RVItbjlQbXZVRk9fU05ucGZsZw?oc=5","date":"2024-12-12","type":"pipeline","source":"Fierce Pharma","summary":"After M&A rumors sparked stock volatility, Bausch + Lomb confirms it's exploring a sale - Fierce Pharma","headline":"After M&A rumors sparked stock volatility, Bausch + Lomb confirms it's exploring a sale","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPT1F6UlkzTVphVzBhM2c4eWZabEthYXp0c1dGYkdvUWpKN2JEVUc5U1ZyZkxsYURpMnJQekd3alJiSnVwenplelFBRXMzeVdaMS00WXV2TmY2V1dIR1Y3cXFXdUZyUVExSFNYUzRLSEtldzRMMkNhRnA1WkpEWDhFSFZfSFVrZEQtdjdxTUFTSTNROFpUeWQ2ZVh3T0ppbzEwWEU2QW5wU0FFblBsZlNPNHNveFJQNmRTQVNzUF9Ldw?oc=5","date":"2023-08-02","type":"deal","source":"Reuters","summary":"Bausch + Lomb's Saunders doesn't expect more big deals in the near term - Reuters","headline":"Bausch + Lomb's Saunders doesn't expect more big deals in the near term","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxPYXBZVjkwQ3pORThiTUdtUlpXMWNpMlpYVUFacUhHOXJHZlhobWZxV1pqQXhBVkoyLU5TRzZiTUFIUWVmUEVhdmRMdWh0YlgyQkU1dXFuY0hfWEp4OW8zS05PeWk0bFFEMWVsMThpbjVPcXN3cVV2d1pqeC1CSHEzT3RmbzJ6dw?oc=5","date":"2023-02-15","type":"pipeline","source":"BioPharma Dive","summary":"Brent Saunders appointed Bausch + Lomb CEO in return to pharma C-suite - BioPharma Dive","headline":"Brent Saunders appointed Bausch + Lomb CEO in return to pharma C-suite","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOYlZLc2RwdnRzbTFFczdxUG9WM1Y5R0JhWWVaQ3l1MFpJekZsMzExYURRdFBCZ3VoMDVyTHpIUDAxMEgyU0JINXh0V3dsTElqQUVlTl94bFhDYlVPcG8xTkJvUkdBVHFfTHpWSjY3XzhBV3B2UWQ5bThxcW9ZNk5LYlNpZF9oQURHcFZiWUdaVVRyakthZ1ktMlhKb2M2bENuWDI2bWx4RVN1ZnBEZlNqWkd0Uks0YTF5WWt0eA?oc=5","date":"2022-05-02","type":"pipeline","source":"The Globe and Mail","summary":"Laval-based pharmaceutical company Bausch + Lomb plans US$788-million IPO - The Globe and Mail","headline":"Laval-based pharmaceutical company Bausch + Lomb plans US$788-million IPO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE9walpfS1hXVXFZZWtvX29OajVyamRST21QN0RKVHl5QVQ0MVBCc2hiaV9qOUdPdkFjblBJOFE1TkN2MUpTVkNMeHprOGxhT00ySk03QTljS3BkMlNnQlhTcU1DNXVhOGtGWkdBMDNkdVB1cGlVV2Z3VA?oc=5","date":"2021-04-07","type":"pipeline","source":"Rochester Beacon","summary":"Bausch + Lomb’s uncertain future - Rochester Beacon","headline":"Bausch + Lomb’s uncertain future","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAJBVV95cUxOb0VKWDdOc0E1SkRtTmxSV0xCaHJXWVl2MjhqdkppSkJRdDhzM1h1V29yNmYzS2pUVEFodGVmNTNMX3hPOG5vR1FobzJHMFlmLVgwZU8ybXdrdXQ3djYxRFJXdGdmaWVLUktYQk1JTDVGMUg5dGV3SzlyelhGNDd2OVdwb3g2bUhaMkliY1NXWTVxbkM2d1NJU3hHVGs3d0E0WkJmc2FiRDJZT1ZGQkJTWGVtSlRrVXhvazRyc1ZXeXlLZW5DdWRRTjI2X0Rrc2E2QUJyUVlxWl96TXdrOG4wN2g5OXZfd29rcTVXaGJWUkdjNXVhbHN4VlBldXVWdkF5NGo3MzhtUVYtWDRtS003NTFiWEZtakhw?oc=5","date":"2019-02-19","type":"deal","source":"prnewswire.com","summary":"Bausch Health Acquires Eton Pharmaceuticals' EM-100 Investigational Eye Drop For The Treatment Of Itchy Eyes Associated With Allergies - prnewswire.com","headline":"Bausch Health Acquires Eton Pharmaceuticals' EM-100 Investigational Eye Drop For The Treatment Of Itchy Eyes Associated ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxPa1V0YmVoS2kxSkdrbjJ2VTdQOHNZYUdUQTduTFVSN0hiNVdtMnQwVHBudmJBNjlwYTdXQUs4M0d0M2ZpTVJoeVZYWjRkX3FoLTlCSDl3cjRodDZuN1l4aDgxWVZMV3QxU3Vnb3VHNmc1S3JQdkhGS1FMQmk2c04wOTJIRXR1STlES1h3M2w4SUw2RS1TeDB0OXdWX0tQM2FGUHgzRGpyTW1mTU9SQU5wREJQNWM3b1ZUOU0zRlktNDk0YVhDQXEtWGN5UV8zaWIwSXhqc3RBTVh2Z0JwSllKbUF1SEVZU1E?oc=5","date":"2018-05-08","type":"pipeline","source":"Democrat and Chronicle","summary":"Valeant to change name to Bausch Health Cos. in July - Democrat and Chronicle","headline":"Valeant to change name to Bausch Health Cos. in July","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAJBVV95cUxPXzJDTGZzX2V2U3pxTEFidUJlcE5ZVFlGQkNQV3FzTy12YU04eElrOFNmQUV2R3d5emhDeldJY2JnYnhZSHFPTTgweXpCZS1Vc3ExcmdWa1JpT0JIbzNjcjJHWFRRQV9MdXdWOW84VTAtWmZRYXhiaTRfVUM3NTlSVTVqOVZPMTJCVkRXTHctZWwxd1hKVEctcXlqckNtVFVscXVXd1NIT2hpdGIwcXRIZWljOGNRcmVGNFgtUlZGY1RoUWdhNGRiNVZVc0lSMUZYUUJ6cmxhWi1jTmZtOW5xRm1laVN1clBXcklMbFR6M0xjeFJtLUtNX0NuaGF1Q1NXV0pzNGhwbTMwZW5LQWFGeW9iYlBTclAzWHFyeW5IQXY?oc=5","date":"2017-12-22","type":"regulatory","source":"prnewswire.com","summary":"Bausch + Lomb Receives FDA Approval of LUMIFY™ - The Only Over-The-Counter Eye Drop With Low-Dose Brimonidine For The Treatment Of Eye Redness - prnewswire.com","headline":"Bausch + Lomb Receives FDA Approval of LUMIFY™ - The Only Over-The-Counter Eye Drop With Low-Dose Brimonidine For The Tr","sentiment":"positive"}],"patents":[],"drugCount":54,"phaseCounts":{"phase_3":20,"phase_2":7,"marketed":25,"discontinued":1,"phase_1":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}